| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
25,750,000 |
| Market
Cap: |
461.44(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.1 - $22.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 14.6 |
| Insider 6 Months : 14.6 |
| Insider 3/6 Months : 29.5 |
|
| Guru Rank Number : 140 |
| Guru Rank Value : 7.2 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Harrow Health engages in the development, production and sale of medications. Co. owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical businesses. Through its subsidiaries, Visionology, Inc., which provides an online eye health platform; Surface Ophthalmics, Inc., which is focused on development and commercialization of therapeutics for ocular surface diseases; and Melt Pharmaceuticals, Inc., which is focused on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
179,000 |
179,000 |
257,300 |
699,568 |
| Total Buy Value |
$1,948,031 |
$1,948,031 |
$2,938,957 |
$7,583,356 |
| Total People Bought |
2 |
2 |
3 |
3 |
| Total Buy Transactions |
7 |
7 |
13 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
40,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$504,800 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Boll Andrew |
Chief Financial Officer |
• – – |
2023-07-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
346,500 |
670,519 |
|
- |
|
| Saharek John P. |
Chief Commercial Officer |
• – – |
2023-07-18 |
4 |
D |
$18.23 |
$1,988,528 |
D/D |
(109,080) |
222,197 |
|
- |
|
| Saharek John P. |
Chief Commercial Officer |
• – – |
2023-07-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
277,200 |
331,277 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2023-07-18 |
4 |
D |
$18.23 |
$5,468,417 |
D/D |
(299,968) |
2,009,661 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2023-07-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
762,300 |
2,309,629 |
|
- |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2023-01-02 |
4 |
D |
$14.76 |
$141,726 |
D/D |
(9,602) |
268,461 |
|
- |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,000 |
278,063 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2023-01-02 |
4 |
D |
$14.76 |
$519,242 |
D/D |
(35,179) |
1,484,962 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2023-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
88,000 |
1,520,141 |
|
- |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2022-12-14 |
4 |
B |
$10.52 |
$4,536,045 |
I/I |
431,183 |
175,000 |
1.5 |
95% |
|
| Lindstrom Richard L Md |
Director |
– • – |
2022-09-30 |
4 |
AS |
$12.62 |
$504,800 |
I/I |
(40,000) |
26,100 |
|
54% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2022-09-28 |
4 |
B |
$9.77 |
$108,354 |
I/I |
11,085 |
158,817 |
1.5 |
82% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2022-04-13 |
4 |
B |
$6.76 |
$86,785 |
I/I |
12,832 |
157,732 |
1.5 |
40% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2022-04-12 |
4 |
B |
$6.75 |
$192,717 |
I/I |
28,557 |
154,900 |
1.5 |
41% |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2022-02-19 |
4 |
D |
$7.87 |
$162,161 |
D/D |
(20,605) |
252,563 |
|
- |
|
| Boll Andrew |
Chief Financial Officer |
• – – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
273,168 |
|
- |
|
| Saharek John P. |
President, ImprimisRx |
• – – |
2022-02-19 |
4 |
D |
$7.87 |
$204,014 |
D/D |
(25,923) |
54,077 |
|
- |
|
| Saharek John P. |
President, ImprimisRx |
• – – |
2022-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
80,000 |
|
- |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2022-01-28 |
4 |
B |
$6.89 |
$43,686 |
I/I |
6,343 |
150,000 |
1.5 |
9% |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2022-01-20 |
4 |
D |
$8.33 |
$594,812 |
D/D |
(71,406) |
1,407,141 |
|
- |
|
| Baum Mark L |
Chief Executive Officer |
• • – |
2022-01-20 |
4 |
OE |
$2.40 |
$300,000 |
D/D |
125,000 |
1,478,547 |
|
- |
|
| Lindstrom Richard L Md |
Director |
– • – |
2021-09-24 |
4 |
AS |
$10.04 |
$39,156 |
I/I |
(3,900) |
66,100 |
|
-18% |
|
| Lindstrom Richard L Md |
Director |
– • – |
2021-09-16 |
4 |
AS |
$9.02 |
$52,677 |
I/I |
(5,840) |
70,000 |
|
-25% |
|
| Lindstrom Richard L Md |
Director |
– • – |
2021-09-15 |
4 |
AS |
$9.09 |
$128,714 |
I/I |
(14,160) |
75,840 |
|
-18% |
|
| Opaleye Management Inc. |
10% Owner |
– – • |
2021-08-19 |
4 |
B |
$8.45 |
$443,363 |
I/I |
52,500 |
150,000 |
1.5 |
4% |
|
181 Records found
|
|
Page 2 of 8 |
|
|
0.51 (2.93%) 
